FCPA and Other International Issues PwC. Presenters Jonathon Kellerman Partner, Pharmaceutical and...

26
FCPA and Other International Issues

Transcript of FCPA and Other International Issues PwC. Presenters Jonathon Kellerman Partner, Pharmaceutical and...

Page 1: FCPA and Other International Issues PwC. Presenters Jonathon Kellerman Partner, Pharmaceutical and Life Sciences PricewaterhouseCoopers (267) 330-2466.

FCPA and Other International Issues

Page 2: FCPA and Other International Issues PwC. Presenters Jonathon Kellerman Partner, Pharmaceutical and Life Sciences PricewaterhouseCoopers (267) 330-2466.

Presenters

Jonathon KellermanPartner, Pharmaceutical and Life SciencesPricewaterhouseCoopers(267) [email protected]

Rita Gail JohnsonDirector, Corporate Business DevelopmentEurasia Group(212) [email protected]

Page 3: FCPA and Other International Issues PwC. Presenters Jonathon Kellerman Partner, Pharmaceutical and Life Sciences PricewaterhouseCoopers (267) 330-2466.

Section one

Why should you be concerned with FCPA?

Identifying international risks in a changing global landscape

An approach to implementing an FCPA compliance program

Page 4: FCPA and Other International Issues PwC. Presenters Jonathon Kellerman Partner, Pharmaceutical and Life Sciences PricewaterhouseCoopers (267) 330-2466.

PricewaterhouseCoopers

Compliance Professionals Face the “Perfect Storm”

Future relevance

and span of control

* Continued mergers and acquisitions and

growth into emerging markets

* Increased enforcement

and investigations

Page 5: FCPA and Other International Issues PwC. Presenters Jonathon Kellerman Partner, Pharmaceutical and Life Sciences PricewaterhouseCoopers (267) 330-2466.

PricewaterhouseCoopers

Enforcement & Investigations – Evidence of FCPA Activity

• Huge current wave of DOJ/SEC enforcement• FCPA listed as one of US DOJ Fraud Division’s top three priorities [Source:

ACFE Conference speech by DOJ rep. John Richter – July 2005]• More cases filed and active from 2003 to 2005 than in all previous years• Largest fines/penalties ever

- Titan case - $28.5 million- ABB case - $16.4 million- DPC case - $ 4.5 million- Statoil case - $10.5 million and monitor- Schnitzer Steel case - $7.5 million (voluntary disclosure)

• Failure of mergers- Lockheed- Titan

• According to US DOJ, 11 companies made voluntary disclosures of FCPA problems in March 2006 alone

Page 6: FCPA and Other International Issues PwC. Presenters Jonathon Kellerman Partner, Pharmaceutical and Life Sciences PricewaterhouseCoopers (267) 330-2466.

PricewaterhouseCoopers

Possible Sources of the Upswing in FCPA Enforcement

• Increased scrutiny due to Sarbanes Oxley 404 testing and controls work

• Different environment post Enron/WorldCom

• More co-operation between international government regulators

• Elevated whistleblower activity

• New lead people at DOJ/SEC (Mendelsohn/Grime)

• US Senate’s approval of the U.N. Convention Against Corruption

• US working in context of the OECD Convention

Page 7: FCPA and Other International Issues PwC. Presenters Jonathon Kellerman Partner, Pharmaceutical and Life Sciences PricewaterhouseCoopers (267) 330-2466.

PricewaterhouseCoopers

Looking at the Major Trends in FCPA Enforcement

• Simultaneous investigations

• Dramatic increase in scrutiny of emerging markets (China, India, Russia)

• More self reporting (“race to DOJ effect”)

• Much bigger penalties / settlements - Disgorgement of profits

• Unique charging

- Charitable donations / expansion of Foreign Official definition

• More expansive interpretation of statute language - Give value to/something of value…- …Foreign official…- …For the purpose of obtaining or retaining business

• Increased scrutiny of acts of others- Parent company responsibility for acts of a subsidiary- Liability for acts of a distributor

• Deferred prosecution, non-prosecution

• Use of independent compliance monitors

Page 8: FCPA and Other International Issues PwC. Presenters Jonathon Kellerman Partner, Pharmaceutical and Life Sciences PricewaterhouseCoopers (267) 330-2466.

Page 8PricewaterhouseCoopers

Considerations of High Risk Business Activities

• High-risk governmental decision making (i.e., pricing, reimbursement, formulary listing, bulk purchasing and licensing)

• Define and identify government officials

• Various payments:- to or on behalf of health care professionals for attendance at foreign congresses,

symposia or company events

- for meals, permitted gifts, permitted entertainment incident to education or promotions about company products

- for compensated services/activities (e.g., advisory boards, speaker arrangements, article writing, clinical trials)

- for research funds or grants to doctors from government or state owned hospitals

• Charitable contributions

• Contracting with third-party agents

• Fair market value

• Internal training, monitoring, auditing and reporting of FCPA risks

Page 9: FCPA and Other International Issues PwC. Presenters Jonathon Kellerman Partner, Pharmaceutical and Life Sciences PricewaterhouseCoopers (267) 330-2466.

Page 9PricewaterhouseCoopers

Considerations of High Risk Business Activities

Corporate policies should also establish a basic expectation for having process and controls related to books and records requirements, specifically accounting for the following:

• Cash transactions and wire transfers

• Facilitation payments (if permitted)

• Gifts, travel and entertainment expenses (especially with government officials) and the general practices with respect to using cash and/or credit cards

• Individual expense reports (and the ability to capture data related to government officials)

• Advance, petty cash and commission payments to employees or 3rd parties

• Classification of payment types in the general ledger (e.g., charitable contributions and donations, payments to health care professionals, sponsorship of health care professionals to international congresses and symposia)

• Approval limit policies

Page 10: FCPA and Other International Issues PwC. Presenters Jonathon Kellerman Partner, Pharmaceutical and Life Sciences PricewaterhouseCoopers (267) 330-2466.

PricewaterhouseCoopers

Core Decision Points and the Potential for Corruption

Registration Selection Procurement DistributionService

Delivery

EfficacyLabelingMarketingUseWarningsFull registrationRe-evaluation

of older drugs

Determine

budgetAssess

morbidity profileDetermine drug

needs to fit

morbidity profileCost-benefit

analysis of drugsConsistency

with WHO criteria

Determine

model of

supply/distributio

nReconcile

needs and

resourcesDevelop criteria

for tenderIssue tenderEvaluate bidsAward supplierDetermine

contract termsMonitor orderMake paymentQA

Receive and

check drugs with

orderEnsure

appropriate

transportation

and delivery to

health facilitiesAppropriate

storageGood inventory

control of drugsDemand

monitoring

Consultation

with health

professionalsIn-patient careDispensing of

pharmaceuticalsAdverse drug

reaction

monitoringPatient

compliance with

prescription

Page 11: FCPA and Other International Issues PwC. Presenters Jonathon Kellerman Partner, Pharmaceutical and Life Sciences PricewaterhouseCoopers (267) 330-2466.

Section two

Why should you be concerned with FCPA?

Identifying international risks in a changing global landscape

An approach to implementing an FCPA compliance program

Page 12: FCPA and Other International Issues PwC. Presenters Jonathon Kellerman Partner, Pharmaceutical and Life Sciences PricewaterhouseCoopers (267) 330-2466.

PricewaterhouseCoopers

What are other international risks?

Country Risk• Centralization of power, as in Russia and China• Destabilizing effect of Presidential coup in Thailand

Economic Policy Risk• Local and foreign pharmaceutical companies in

India oppose government price controls• French government recommends limitations on drug

reimbursement• Differential treatment of domestic and foreign drug

makers in China

Local Risk• Regional governments in China act independently of

national government on IPR enforcement

Political Risks

Page 13: FCPA and Other International Issues PwC. Presenters Jonathon Kellerman Partner, Pharmaceutical and Life Sciences PricewaterhouseCoopers (267) 330-2466.

PricewaterhouseCoopers

Globalization has led to increasing acceptance of political risk

Imperative for BusinessNo matter how local your business, international politics can have an impact. By identifying and monitoring political risk, you will better understand your company’s global exposures and balance your risk appetite against achievement of business objectives

Imperative for BusinessNo matter how local your business, international politics can have an impact. By identifying and monitoring political risk, you will better understand your company’s global exposures and balance your risk appetite against achievement of business objectives

Political Risk DefinitionAny political change that alters the expected outcome and value of a given economic action, by changing the probability of achieving business objectives

Political Risk DefinitionAny political change that alters the expected outcome and value of a given economic action, by changing the probability of achieving business objectives

Impact of Political ChangePolitics influences how markets operate - often the most unpredictable economic events are political in origin

Impact of Political ChangePolitics influences how markets operate - often the most unpredictable economic events are political in origin

Page 14: FCPA and Other International Issues PwC. Presenters Jonathon Kellerman Partner, Pharmaceutical and Life Sciences PricewaterhouseCoopers (267) 330-2466.

PricewaterhouseCoopers

Political Risk – What to monitor

GOVERNMENT

Policies and attitudes toward business; regulation, taxation, infrastructure, privatization, foreign ownership, corruption

ECONOMY

Fiscal and monetary policy, foreign exchange rates, inflation, economic growth

SOCIETY

Demographic shifts, social behaviors, societal tensions/conflicts

SECURITY

Cross-border conflicts, terrorism, emergencies, biosecurity threats, environmental disasters

Page 15: FCPA and Other International Issues PwC. Presenters Jonathon Kellerman Partner, Pharmaceutical and Life Sciences PricewaterhouseCoopers (267) 330-2466.

PricewaterhouseCoopers

Political risks across the BRICs

Country Risk

Economic Policy Risk

Local Risk

CHINA: An increasingly predictable business environment for new and existing companies, but substantial country risk.

INDIA: New entrants face bureaucratic procedures, but country stability and increasingly market-oriented policies. Some economic policy risk, but little country risk.

BRAZIL: Difficult for new entrants, but country stability, an improving bureaucracy and increasingly market oriented policies. Risk is localized, depending on sector and competitors.

RUSSIA:

Country risk associated with increasing centralization of political power

Economic policy risk created by centralized power

Local risk from domestic competitor’s political connections.

Source: Eurasia Group

Page 16: FCPA and Other International Issues PwC. Presenters Jonathon Kellerman Partner, Pharmaceutical and Life Sciences PricewaterhouseCoopers (267) 330-2466.

PricewaterhouseCoopers

Political risk can be anticipated, prepared for and mitigated

Managing political risk effectively requires• Understanding the potential business consequences of political risk• Employing a systematic, structured way of thinking about political risk • Embedding political risk considerations into operating business

processes• Having a portfolio view of risk to understand the implications and

interdependencies between political risk and other business risks• Obtaining geo-political intelligence relevant to long-term challenges

and opportunities• Ongoing monitoring, to ensure implementation reflects changing

political risk scenarios

Page 17: FCPA and Other International Issues PwC. Presenters Jonathon Kellerman Partner, Pharmaceutical and Life Sciences PricewaterhouseCoopers (267) 330-2466.

PricewaterhouseCoopers

Key risk change signals

For new or existing investment, operations, sales or supply chains in international markets, monitor the following:

• Rapid economic growth, instability or deterioration

• Increasing foreign investment

• Imminent change in government leadership

• Political bodies are debating regulatory changes

• Multilateral agencies are considering changes to trade agreements

• Demographic shifts

• Social unrest is common or likely

• Security issues are a concern and not adequately addressed

Page 18: FCPA and Other International Issues PwC. Presenters Jonathon Kellerman Partner, Pharmaceutical and Life Sciences PricewaterhouseCoopers (267) 330-2466.

PricewaterhouseCoopers

Benefits of a proactive approach to political risk

• Improved measurement using risk-adjusted evaluation of international performance

• Ability to make better, more timely, decisions about international investments and operations

• Identification of opportunities as well as risks presented by political shifts

• Time and opportunity to implement appropriate risk mitigation steps

• Minimization of reputational risk

• Realization of globalization objectives while protecting against unwanted surprises

Page 19: FCPA and Other International Issues PwC. Presenters Jonathon Kellerman Partner, Pharmaceutical and Life Sciences PricewaterhouseCoopers (267) 330-2466.

Section three

Why should you be concerned with FCPA and other international issues?

Identifying international risks in a changing global landscape

An approach to implementing an FCPA compliance program

Page 20: FCPA and Other International Issues PwC. Presenters Jonathon Kellerman Partner, Pharmaceutical and Life Sciences PricewaterhouseCoopers (267) 330-2466.

Page 20PricewaterhouseCoopers

A Plan for Implementing a Global FCPA Compliance Program

Step 1 - Ensure corporate standards address necessary elements of FCPA compliance and establish minimal compliance thresholds

Outcomes – updated corporate documents and communications that address key messages on anti-bribery, anti-corruption, payments to government officials, internal controls, etc.; and a formal communications and certification plan

(intranet access, web training, messages from senior leadership)

Step 2 - Evaluate corporate policies to ensure that they cover high-risk activities

Outcomes – a set of “global” standards and expectations for controls around high- risk business activities and that establish a basic expectation for having process

and controls related to books and records requirements

Step 3 – Provide management training on FCPA compliance

Outcomes – promote compliance by educating local management on the key tenets of FCPA, the inter-communications of regulatory agencies, expectations

of international and local country “pharma codes,” risks of whistleblowers, increases in local regulatory agency investigations, etc.

Page 21: FCPA and Other International Issues PwC. Presenters Jonathon Kellerman Partner, Pharmaceutical and Life Sciences PricewaterhouseCoopers (267) 330-2466.

Page 21PricewaterhouseCoopers

A Plan for Implementing a Global FCPA Compliance Program

Step 4 – Assess FCPA compliance and document processes and controls in select/higher risk subsidiaries (leverage Transparency International Corruption Index, revenue data, anecdotal information to select regional representation)

Outcomes – Risk assessment findings by affiliate; detailed process maps for each high-risk business activity; and recommendations for corrective action/remediation

Step 5 – Develop a “gloabl” FCPA compliance implementation program

Outcomes – a formal, standard set of processes and model policies and procedures to be implemented locally; an implementation “tool kit”; recommended monitoring controls, and internal reporting protocols to meet the FCPA compliance

requirements

Step 6 – Conduct subsidiary “pilot” programs focused on testing the execution of the FCPA compliance implementation program locally

Outcomes – Step 5 deliverables, tailored and refined based on pilot implementation.

Page 22: FCPA and Other International Issues PwC. Presenters Jonathon Kellerman Partner, Pharmaceutical and Life Sciences PricewaterhouseCoopers (267) 330-2466.

Page 22PricewaterhouseCoopers

A Plan for Implementing a Global FCPA Compliance Program

Step 7 – To support global roll-out of the FCPA compliance implementation program, conduct global training on FCPA, company policies, the FCPA compliance implementation program and the implementation “tool kit”

Outcomes – Web casts and select live meetings designed to train local management on FCPA, company expectations for implementation of the FCPA compliance program and the tools to promote successful implementation

Step 8 – Global implementation of the FCPA compliance program

Outcomes – each subsidiary will have implemented the FCPA compliance program by a designed date

Step 9 – Perform post-implementation validation reviews at select subsidiaries (focusing on those that did not receive implementation assistance) to assess management’s implementation of the FCPA compliance program

Outcomes – Reports on the results of post-implementation reviews for each subsidiary with recommendations for improvement; and transferable internal

audit programs for ongoing FCPA compliance monitoring

Page 23: FCPA and Other International Issues PwC. Presenters Jonathon Kellerman Partner, Pharmaceutical and Life Sciences PricewaterhouseCoopers (267) 330-2466.

Page 23PricewaterhouseCoopers

Considerations for Compliance Monitoring Protocols

• Aggregate spend analysis reports (by HCP, by product, by geography, by program types)

• GL account reports by payment classification type, etc.

• Dollar threshold/limit triggers

• Frequency and amounts of expense report submissions (how many not approved, etc.)

• Number and type of red flags raised during due diligence of third parties

• Hotline calls and follow up investigations

• Training - number of people trained, frequency of training, training certification

Page 24: FCPA and Other International Issues PwC. Presenters Jonathon Kellerman Partner, Pharmaceutical and Life Sciences PricewaterhouseCoopers (267) 330-2466.

Page 24PricewaterhouseCoopers

Considerations for Awareness and Training Content

• Background on FCPA and its core components - anti-bribery and books and records standards; examples of settlements, etc.

• Corporate standards

• Company-wide policies

• Case studies addressing unique local country scenarios

• Company resources and tools available

• Implementation plan and the roadmap to successful implementation (“tool kit”)

Page 25: FCPA and Other International Issues PwC. Presenters Jonathon Kellerman Partner, Pharmaceutical and Life Sciences PricewaterhouseCoopers (267) 330-2466.

Page 25PricewaterhouseCoopers

Considerations for Selecting Affiliates for Implementation Pilots

• Size of operations and field force

• Revenues

• Corruption indices (Transparency International)

• Industry knowledge of regulatory activity

• Insight into the quality of leadership and the control environment, etc.

• Locations that have not been audited in the past

• Occurrence of prior incidents, related response and remediation

• Responses to FCPA survey, if one is used

Page 26: FCPA and Other International Issues PwC. Presenters Jonathon Kellerman Partner, Pharmaceutical and Life Sciences PricewaterhouseCoopers (267) 330-2466.

Page 26PricewaterhouseCoopers

Concluding Thoughts….

• The world has truly changed

• Yesterday’s solutions no longer viable

• Regulatory Agency “expectations” very high – programs need to “raise the bar”

• Must have a documented rigorous, robust and proactive program

• “You get what you test.” If you aren’t looking, you are NOT going to find it

• Need “smoke alarms” in your controls to avoid a train wreck

• Develop compliance culture

• “Floor” is US DOJ 04-02